PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Cancer Res. Author manuscript; available in PMC Jun 14, 2006.
Published in final edited form as:
PMCID: PMC1479314
NIHMSID: NIHMS8365
Colorectal papillomavirus infection in colorectal cancer patients
Sohrab Bodaghi,1 Koji Yamanegi,1 Shu-Yuan Xiao,2 Maria Da Costa,3 Joel M. Palefsky,3 and Zhi-Ming Zheng1
1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
2Pathology and Internal Medicine, University of Texas Medical Branch, Galveston, Texas
3Department of Medicine, University of California, San Francisco, San Francisco, California
Corresponding author: Zhi-Ming Zheng, M.D., Ph.D., HIV and AIDS Malignancy Branch, Center for Cancer Research, NCI/NIH, 10 Center Dr. Rm. 10 S255, MSC-1868, Bethesda, MD 20892-1868, Tel.: 301-594-1382, Fax: 301-480-8250, Email: zhengt/at/exchange.nih.gov
Purpose: Infection with human papillomaviruses (HPVs) is associated with the development of cervical cancer, but whether HPVs have a role in colorectal cancer remains controversial.
Experimental Design: To determine the relationship between HPV and colorectal cancer, we performed a retrospective, controlled study using tumor and tumor-adjacent colorectal tissues dissected from patients with colorectal cancer, as well as colorectal tissues from control individuals with no cancer. The samples were processed in a blinded fashion for nested PCR and in situ PCR detection of HPV DNAs. The PCR products were gel purified and sequenced for HPV genotyping.
Results: We found that colorectal tissues from 28 (51%) of 55 patients with colorectal cancer were positive for HPV DNA. Colorectal tissues from all 10 control individuals were negative for HPV DNA (P=0.0034). Of the 107 usable (GAPDH+) samples collected as paired colorectal tissues (tumor and tumor-adjacent tissues) from the patients, 38 (36%) had HPV16 (n=31), HPV18 (n=5), or HPV45 (n=2), with HPV DNA in both tumor and tumor-adjacent tissues of 10 paired samples, 13 in only the tumor, and 5 in only tumor-adjacent tissues. In situ PCR detection of the tumor tissues confirmed the presence of HPV DNA in tumor cells.
Conclusion: Our results suggest that colorectal HPV infection is common in patients with colorectal cancer, albeit at a low DNA copy number, with HPV16 being the most prevalent type. HPV infection may play a role in colorectal carcinogenesis.
Keywords: Human papillomavirus type 16, Viral oncogenesis, Tumor virus infection, PCR
Human papillomavirus (HPV) infection of epidermal or mucosal epithelial cells causes benign and sometimes malignant neoplasms. Certain types of HPVs, such as HPV16, 18, 31, and 45, are detected frequently in anogenital cancers, particularly cancer of the cervix and anus, and are thus considered to be high-risk or oncogenic. Integration of the viral genome into the cancer cell genome is characteristic of infection by these HPVs. Other types of HPV, such as low-risk or non-oncogenic HPV6 and HPV11, induce benign anogenital warts and are rarely found in anogenital malignancies (1,2).
HPV DNA has been detected in tumor tissues of head and neck cancer (3,4), oral cancer (5), esophageal cancer (6,7), and some skin cancers (8,9), as well as lung cancer (10,11). Detection of HPV DNA in colorectal cancer tissues by in situ hybridization (12) and PCR (13-17) has suggested that HPV infection might be associated with the carcinogenesis of colorectal cancer. However, HPV DNA was not detectable by regular PCR in one earlier study (18) and a survey of HPV16 virus-like particle (VLP) antibodies in patients with epithelial cancers also failed to provide an association of HPV with colorectal cancer (19) challenging the association of colorectal cancers with HPVs. As a result, we felt that a well-controlled study would be more informative. In the present report, we performed a retrospective, controlled study in which colorectal cancers and tissues adjacent to the cancers were surgically collected from patients with colorectal cancer and subjected to nested PCR and in situ PCR detection of HPV DNAs.
Sample acquisition and preparation. Colorectal tissues were obtained from 55 patients with colorectal cancer as paired tissue specimens by dissection of tumor and tumor-adjacent tissues. The first set of paired colorectal tissues, collected from 45 patients in the Baltimore area, was provided by Dr. Curtis Harris at NCI. The second set of paired colorectal tissues was collected from 10 patients in the Houston area by one of the authors (S.Y. X). In the second set of tissues, the tumor-adjacent tissues were dissected from an area approximately 20 cm away from the tumor lesions. Normal colorectal tissues dissected from 10 individuals who died accidentally were also provided by Dr. Curtis Harris at NCI and were used as negative controls. Of the 55 colorectal cancer patients, 53 patients had adenocarcinoma in various colon locations, 1 had rectal squamous carcinoma, and 1 had descending colon adenoma. Of the 55 patients, 32 were male and 23 female; 22 were Black, 30 White, 2 Asian, and 1 Hispanic; and their ages ranged from 35 to 82. Among the 10 controls without colorectal cancer, 4 were Black, 5 White, and 1 Asian, and they ranged in age from 21 to 75. Specific locations of the cancers and their adjacent tissues are described in Table 1.
Table 1.
Table 1.
Colorectal HPV infection in the patients with colorectal cancer
All specimens were frozen immediately following the sample dissections and were kept at -70°C until further analysis. About 100 mg of each specimen was randomly coded and screened in a blinded manner for the presence of HPV DNAs. Each colorectal tissue was homogenized in an Eppendorf tube in 1 ml TRIzol solution (Invitrogen, Carlsbad, CA) using an electric homogenizer (Omni International, Marietta, GA) with a separate disposable probe for each tissue. The isolated DNA was dissolved in ~200 μl of 8 mM NaOH and adjusted to pH 7.0 with 1 M HEPES. Various precautions were taken to minimize sample-to-sample cross-contamination, including limiting the tissue processing and DNA extraction to a maximum of ten samples per day.
HPV DNA detection. HPV DNA was first amplified with pooled HPV L1 consensus primers, PGMY09/11 (20). This pooled primer set contains five 5′ primers and thirteen 3′ primers and amplifies more than 25 types of anogenital HPVs. This was followed by nested PCR using an internal primer set, GP5/6 (21,22). Each PCR reaction was carried out in a total volume of 50 μl containing 5 μl purified DNA, 1X AmpliTaq Gold PCR buffer (10 mM Tris-HCl [pH 8.3], 50 mM KCl), 2.5 mM MgCl2, 200 μM of each dNTP, 100 nM of pooled PGMY09/11 primers, and 1.25 U of AmpliTaq Gold DNA polymerase (Perkin Elmer, Foster City, CA). PCR was carried out by activation of AmpliTaq Gold DNA polymerase for 9 min at 94°C and followed by 40 cycles of 30 sec each at 94°C, 55°C, and 72°C, with a final extension of 7 min at 72°C. One microliter of the first-run PCR reaction was used as a template for the nested PCR. The conditions for the nested PCR (40 cycles) were identical to the first-run PCR with the exception of the use of 100 nM of the GP5/6 primers and annealing at 40°C for 30 sec. The amplified products with the expected size (141 bp) (Fig. 1) were gel purified and sequenced. The individual sequence was then used in a BLAST search against GenBank HPV sequences (NCBI).
Fig. 1
Fig. 1
Schematic diagram of HPV16 genome as a representative for relative positions of primers and probes used in this study. The bracket line in the middle of the panel represents a linear form of the virus genome for better presentation of head-tail junctions, (more ...)
Detection of HPV16 E6 (16E6), HPV18 E6 (18E6), and HPV45 E6 (45E6) DNA was also carried out by nested PCR, using primers named by the location of their 5′ ends in each virus genome. The first-run PCR primer pairs for 16E6 were Pr80 (5′-CTGACTCGAG/TTTATGCACCAAAAGAGAAC-3′) and Pr625 (5′-GATCAGTTGTCTCTGGTTGC-3′); for 18E6, Pr79 (5′-CTGACTCGAG/AGATGTGAGAAACACACCAC-3′) and Pr749 (5′-CTCGTCGGGCTGGTAAATGT-3′); and for 45E6, Pr113 (5′-TGACGATCCAAAGCAACG-3′) and Pr563 (5′-CCTACGTCTGCGAAGTCT-3′). First-run PCR was followed by re-amplification using nested primer pairs for 16E6, Pr106 (5′-GTTTCAGGACCCACAGGAGC-3′) and Pr562 (5′-GTACTCACCCC/TGATTACAGCTGGGTTTC-3′); for 18E6, Pr 121 (5′-ATCCAACACGGCGACCCTAC-3′) and Pr528 (5′-AGCACGAATGGCACTGGC-3′); and for 45E6, Pr131 (5′-ACCCTACAAGCTACCAGAT-3′) and Pr545 (5′-TTCTTGCCGTGCCTGGTC-3′). The final PCR yielded a 456-bp product for 16E6 (Fig. 1), a 407-bp product for 18E6, and a 414-bp product for 45E6.
All 16E6-positive samples were also examined by nested PCR for the presence of an intact E2 ORF to evaluate the integration of HPV16 DNA into the host genome. This was performed using the HPV16E2 (16E2) primer set Pr3385 (5′-TATTAGGCAGCACTTGGC-3′) and Pr3840 (5′-AATCCAGTAGACACTGTAATAG-3′) for first amplification and another primer set, Pr3439 (5′-CTTGGGCACCGAAGAAACAC-3′) and Pr3790 (5′-TTGGTCACGTTGCCATTCAC-3′), for nested amplification. The final nested PCR yielded a 351-bp product for 16E2 (Fig. 1).
Under these PCR and nested PCR conditions, the detection efficiency for plasmid HPV DNA by nested PCR was limited to 1-10 fg of DNA (equivalent to ~130-1300 HPV genome copies), depending on the type of HPV and the primers used (data not shown).
Dot-blot hybridization. Dot-blot hybridization was performed only for the nested L1 PCR reaction and has been described elsewhere (23). A biotinylated HPV16 L1 probe (nt 6664 to 6684) (Fig. 1) was used for the hybridization at concentration of 1 pmol/ml hybridization solution.
Validation of PCR reactions. Human GAPDH DNA in each DNA sample was screened by PCR amplification using a sense primer, Pr6732 (5′-GTCATCAATGGAAATCCCATCACC-3′), in combination with an antisense primer, Pr7207 (5′-TAATACGACTCACTATAGGGA/CCGTTCAGCTCAGGGATG-3′). This primer set amplifies a 496-bp product and provides an indication of good DNA quality for each sample. Colorectal DNA samples from which GAPDH DNA could not be amplified were dropped from further study.
For HPV amplification from colorectal DNA samples, two water controls were also included for both first-run and nested PCR. If either of the two water controls yielded a false-positive in the nested PCR, the whole set of PCR and nested PCR reactions were started over. A sample was considered to be HPV-positive if PCR products of the expected sizes were detected for both L1 and E6 and were further confirmed by DNA sequencing.
In situ polymerase chain reaction. The randomly labeled colorectal tissues, which had been fixed in 10% buffered formalin for 16-18 hrs at room temperature, were embedded in paraffin and then cut at 7 μm. The sections were placed on silane-coated slides (Labsco, Louisville, KY) and stored at 4°C until use.
The sections were deparaffinized in xylene twice for 10 min each and rehydrated twice for 5 min in each graded ethanol before being put into distilled water. The sections were then digested with 0.8% pepsin (DAKO, Carpinteria, CA) in 0.2 N HCl for 5 min at 37°C and rinsed in DEPC water before being subjected to a hot-start PCR amplification using AmpliTaq Gold DNA polymerase (24,25). The PCR amplification was performed on the slide in 50 μl of reaction solution containing 1X AmpliTaq Gold PCR buffer, 4 mM MgCl2, 200 μM each dATP, dCTP, and dGTP, 60 μM dTTP, 40 pM digoxigenin-11-dUTP solution (DIG) (Roche, Indianapolis, IN), 400 nM of each primer 16E6 Pr106 (sense) and 16E6 Pr562 (antisense), 10 U of AmpliTaq Gold DNA polymerase, and 28 μl water, and covered with Hybaid SureSeal (Hybaid, Franklin, MA). The slide was placed in aluminum foil on the sample block of a thermal cycler that was filled with mineral oil. After first denaturation at 95 °C for 10 min, the section underwent amplification for 30 cycles (95 °C for 1 min, 72 °C for 2 min, and 55 °C for 2 min). After PCR amplification, the sections were washed in stringent wash solution (DAKO) at 50 °C for 60 min. Detection of DIG incorporated into the PCR product was performed with an alkaline phosphatase (AP)-conjugated DIG antibody (DAKO) and visualized in a chromogen solution containing NBT (4-nitroblue tetrazolium chloride)/BCIP (5-bromo-4-chloro-3-indolyphosphate) (DAKO). Nuclear fast red was used for counter-staining. A positive reaction was defined as the presence of a purple-blue precipitate in cell nuclei.
Statistics. A two-tailed Fisher’s exact test was used for the analysis. A two-tailed McNemar’s exact test was used for the analysis of paired categorical data.
In this study, colorectal tissues from 55 patients were dissected as paired samples of the tumor itself and of the noncancerous neighboring tissues. Single tissues were obtained from descending or rectosigmoid regions of 10 control individuals with no cancer. All samples were randomly coded and processed in a blinded manner for screening first for the presence of HPV DNA using L1 consensus primers and then using type-specific E6 primers (Fig. 2) after direct sequencing of the L1 PCR products. Sample codes were decoded after completion of the screening and sequencing. We found that 51% (28/55) of the patients with colorectal cancer were positive for HPV DNA in their colorectal tissues, with no relation to patient race, sex, or age, whereas none of the 10 controls had HPV DNA in their tissues (p=0.0034). Among the 28 patients with HPV DNA in their colorectal tissues, 27 had adenocarcinoma in various colon locations and 1 had rectal squamous carcinoma.
Fig. 2
Fig. 2
Electrophoretic profile of nested PCR products amplified from the HPV L1 and E6 regions. The gel image shows 10 representatives of the 107 nested PCR reactions analyzed with a Agilent 2100 Bioanalyzer. GAPDH DNA from each sample was amplified by PCR for (more ...)
HPV DNA was found in 42% (23/55, p=0.011) of the tumor tissues from the patients and 29% (15/52, p=0.1) of the tumor-adjacent tissues, as compared with none of the controls. Ten paired samples contained HPV DNA in both tumor and tumor-adjacent tissues, 13 only in the tumor, and 5 only in tumor-adjacent tissues from the rectosigmoid area. There was a weak trend for HPV DNA to be detected in the tumor tissues more than the tumor-adjacent tissues (p=0.14 by McNemar’s exact test), but the sample size was too small to detect statistical significance. Among the 38 HPV-positive tissues obtained from the 55 patients, 31 had HPV16, 5 had HPV18, and 2 had HPV45. Among the 10 patients who had HPV DNA in both the tumor and tumor-adjacent tissues, 8 had HPV16, 1 had HPV18, and 1 had mixed rectal HPV16/18 infection with HPV16 DNA in the tumor tissue and HPV18 DNA in the tumor-adjacent tissue. Tissues taken from cecal and ascending colon cancers had similar HPV detection rates as those taken from the rectosigmoid locations (Table 1).
Sequence analysis of all HPV16 isolates from colorectal tissue showed that they were European-derived HPV16 prototype viruses with a T or G at position 350, an A at position 6695, and a G at 6721. Among the 8 paired samples that were HPV16 DNA positive both for the tumor tissue and the tumor-adjacent tissue, 2 paired samples had additional variation in the tumor, but not tumor-adjacent, tissues, in which the 2 viruses varied further from European type virus at positions 6657 or 6675 with a C to T transition and/or at position 6718 with a T to C transition, in addition to varying at positions 350, 6695 and 6721. These additional mutations were observed also in other 3 isolates only from tumor and 2 only from tumor-adjacent tissues.
Initially, we thought that the HPV detection in the tumor-adjacent tissues might reflect cross-contamination during the dissection procedure, since we did not know how the dissection was performed at the hospital or whether the same surgical blade was used to remove first tumor tissues and then tumor-adjacent tissues from the same patient. To address this question, a standardized dissection procedure for tissue sampling, including a new surgical blade for each dissection and a predetermined distance between the tumor-adjacent tissues and the tumor, was applied to another set of 10 paired tissues. In this set, HPV DNA was found in three tumor tissues (3/10) and one tumor-adjacent tissue (1/10). Among these, one paired set of tissues from the rectosigmoid area had HPV16 in both the tumor and tumor-adjacent tissues. Thus, cross-contamination during the dissection procedure appears unlikely to be the reason for the presence of HPV DNA in the tumor-adjacent tissue.
To exclude the possibility of cross-contamination in our laboratory and to make our screening more accurate, 20 DNA samples (9 HPV16-positive and 11 HPV16-negative) from our HPV L1/E6 screening in Bethesda, Maryland, were randomly coded and shipped to the University of California at San Francisco to be analyzed for HPV L1 DNA by nested PCR side-by-side by two scientists (scientist I and II) from two different laboratories in a double-blind manner. Each scientist had two water controls and one SiHa cell reaction as a positive control. Twenty SiHa cells (equivalent to 40 copies of the HPV16 genome) were used by scientist I and thirty cells (equivalent to 60 copies of the HPV16 genome) were used by scientist II. The samples were decoded after the detection and interpretation of the results were complete. As shown in Fig. 3, HPV L1 was reproducibly detected in 8 of the 9 HPV-positive samples by both scientist I and II, with one sample (sample #10) showing false positive for scientist II (Fig. 3A). All PCR products were further confirmed by dot-blot hybridization using an HPV16 L1-specific probe (Fig. 3B). Although the SiHa cell controls in each scientist’s reaction showed no visible PCR products with ethidium bromide staining after gel electrophoresis, they gave weak hybridization signals in the dot-blot hybridization assay, indicating that agarose gel electrophoresis with ethidium bromide staining was not sensitive enough to detect <60 copies of the HPV genome as amplified by our nested PCR.
Fig. 3
Fig. 3
Side-by-side reproducibility of nested PCR and dot-blot analysis of a biotinylated HPV 16 L1 probe. A, agarose gel (1.5%) electrophoresis of amplified HPV L1 DNA from the same sample set (20 samples) given to two scientists (I and II) in a blinded fashion. (more ...)
HPV DNA can be present in host cells in either episomal or integrated form. Integration of the HPV genome into the host cell genome has been identified as a critical step for cancer promotion and progression (26). The episomal form of HPV DNA can be distinguished from the integrated form, respectively, by the detection of an intact E2 gene, which is, in general, disrupted upon HPV integration. Although it is indirect, amplification of the E2 region indicates the presence of episomal HPV DNA in the cells; otherwise, it is assumed that the DNA has integrated (27). Thirty-one of the HPV16 DNA-positive samples were examined for the presence of the intact HPV16 E2 gene (16E2) by nested PCR, and 32% (10/31) of the samples were found to be 16E2-positive (episomal DNA) (Fig. 4), with 22% (4/18) 16E2 detected from the tumor tissues, 39% (5/13) from the tumor-adjacent tissues, and 8% (1/13) from both tissues. The results suggest that viral DNA is integrated relatively frequently in the tumor tissues. However, interpretation is limited by the small sample size, and the fact that some tissues might contain both episomal and integrated forms, as has been reported (26).
Fig. 4
Fig. 4
Electrophoretic profile of nested PCR products amplified from HPV 16 E6 and E2 regions. Gel images are 10 representative of 31 nested PCR reactions analyzed with an Agilent 2100 Bioanalyzer. Water and HPV16 DNA were used as negative and positive controls, (more ...)
Direct in situ PCR amplification with an 16E6-specific primer set was further performed on 3 tumor tissues and 2 tumor-adjacent tissue sections. Each of the 3 tumor tissue sections gave strong in situ amplification signals, which consistently appeared as blue-purple deposits in the nuclei of tumor epithelial cells (Fig. 5).
Fig. 5
Fig. 5
Detection of HPV16 DNA in colorectal tissues by in situ PCR. A, dark-blue nuclear staining indicates the many HPV16 DNA+ tumor epithelial cells in a tumor lesion (x200). B, enlargement (x400) from (A) showing HPV16 DNA+ tumor epithelial cells (arrows) (more ...)
Colorectal cancer is the third most common type of cancer in the USA, with an estimated 147,500 new cases in 2003, and is the second leading cause of cancer mortality, accounting for an estimated 57,100 deaths in 2003 (28). The precise etiology of colorectal cancer is not known.
Although there is substantial evidence implicating high-risk HPV infection in anal cancer (29), a rare neoplasm in the anus, such implication in colorectal cancer remains controversial. In the present study, we demonstrated that HPV infection, particularly with HPV16, is common in colorectal cancer tissues and tissues adjacent to the cancers. The HPV16 DNAs detected from these tissues were all European-derived subtypes. Although additional sequence variations were observed at various positions in these subtypes, these appeared to be more common in the viral DNAs detected from tumor tissues. In two sets of paired tissues, both the tumor and tumor-adjacent tissues contained European-derived HPV16 DNAs, but the additional nucleotide substitutions appeared only in the HPV DNAs detected from tumor tissues, indicating that the viral DNAs in the tumor were different from the ones in the tumor-adjacent tissues in those individuals. In addition, it remains to be investigated whether the patients with HPV infections also had predisposing genetic factors or some form of genetic instability, which has been associated with colorectal cancer (30). Our finding that HPV DNA-positive cells are most common in tumor lesions suggests that HPV might play a role in the pathogenesis of colorectal cancer. However, this presumption is confined by our sample size and needs further confirmation. In a previous study, HPV DNA was found in 27% of colorectal adenomas, 31% of invasive colorectal carcinomas, and 69% of colorectal carcinomas in situ by in situ hybridization using pooled probes for HPV6, 11, 16, 18, 31, 33, and 35 (12). In a separate study, HPV DNA was detected by HPV type-specific E6 PCR in 30% of adenomas and in 53% of carcinomas, with HPV16 as the predominant type (14).
HPV16 was the most prevalent type in colorectal tissues in this report (31/38 positive samples, 82%). A recent study reported a high frequency of colorectal HPV18 infection in colorectal cancer patients in Taiwan (15); however, other studies have shown that colorectal HPV16 infection is common in Taiwanese patients with colorectal cancer (14). We found that colorectal HPV18 infection was much less prevalent in our patients (present in only 5 of 38 samples, less than 13%), one of whom had dual infection with HPV16 and 18. In addition, two patients had HPV45 in their tumor tissues. The finding that HPV infection in the tumor tissues obtained from the cecal and ascending colon regions is as common as in the tissues obtained from rectosigmoid locations suggests that this infection might not be a result of direct spread from anogenital sites.
E2 detection was used in this study as means to evaluate HPV DNA integration, because the viral E2 gene is often disrupted during HPV DNA integration. Although the assay can only detect integrated viral DNA in the absence of episomal HPV DNA, only one-third of the HPV-positive samples had intact E2. Although the overall numbers are low, the viral DNA appeared to have integrated relatively frequently in the tumor tissues relative to the tumor-adjacent tissues.
In summary, colorectal HPV16 infection appears to be common in colorectal cancer-tissues and adjacent non-tumor tissues, suggesting that HPV might play a role in the pathogenesis of colorectal cancer. However, where and how HPVs come to colorectal tissues remains to be investigated.
ACKOWLEDGMENTS
We thank Curtis Harris and Elise Bowman of Laboratory of Human Carcinogenesis, NCI for providing the patient samples and Seth Steinberg at NCI for statistical analysis. We are grateful to Curtis Harris, Douglas Lowy and Robert Yarchoan at NCI for their encouragement in the course of the study and critical comments on the manuscript, Sophia Wang at NCI and Patti Gravitt at at John Hopkins University for providing assistance to detect HPV45. S.B. was supported by an NCI intramural grant 8340201 (to Z.M.Z.).
1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50. [PubMed]
2. Lowy DR, Howley PM. Papillomaviruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields Virology. Fourth edition ed. Vol. 2. Lippincott Williams & Wilkins; Philadelphia: 2001. pp. 2231–64.
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20. [PubMed]
4. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002;8:3187–92. [PubMed]
5. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer. 2003;104:336–44. [PubMed]
6. Shen ZY, Hu SP, Lu LC, et al. Detection of human papillomavirus in esophageal carcinoma. J Med Virol. 2002;68:412–6. [PubMed]
7. Syrjanen KJ. HPV infections and oesophageal cancer. J Clin Pathol. 2002;55:721–8. [PMC free article] [PubMed]
8. Iftner A, Klug SJ, Garbe C, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res. 2003;63:7515–9. [PubMed]
9. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr. 2003:52–6. [PubMed]
10. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001;61:2799–803. [PubMed]
11. Kaya H, Kotiloglu E, Inanli S, et al. Prevalence of human papillomavirus (HPV) DNA in larynx and lung carcinomas. Pathologica. 2001;93:531–4. [PubMed]
12. Kirgan D, Manalo P, Hall M, McGregor B. Association of human papillomavirus and colon neoplasms. Arch Surg. 1990;125:862–5. [PubMed]
13. McGregor B, Byrne P, Kirgan D, Albright J, Manalo P, Hall M. Confirmation of the association of human papillomavirus with human colon cancer. Am J Surg. 1993;166:738–40. [PubMed]
14. Cheng JY, Sheu LF, Meng CL, Lee WH, Lin JC. Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut. 1995;37:87–90. [PMC free article] [PubMed]
15. Lee YM, Leu SY, Chiang H, Fung CP, Liu WT. Human papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect. 2001;34:87–91. [PubMed]
16. Sotlar K, Koveker G, Aepinus C, Selinka HC, Kandolf R, Bultmann B. Human papillomavirus type 16-associated primary squamous cell carcinoma of the rectum. Gastroenterology. 2001;120:988–94. [PubMed]
17. Yu HG, Shun LB, Luo HS, et al. Deletion of the FHIT gene in human colorectal cancer is independent of high-risk HPV infection. Int J Colorectal Dis. 2002;17:396–401. [PubMed]
18. Shah KV, Daniel RW, Simons JW, Vogelstein B. Investigation of colon cancers for human papillomavirus genomic sequences by polymerase chain reaction. J Surg Oncol. 1992;51:5–7. [PubMed]
19. Strickler HD, Schiffman MH, Shah KV, et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev. 1998;7:305–13. [PubMed]
20. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357–61. [PMC free article] [PubMed]
21. Jacobs MV, Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol. 1995;33:901–5. [PMC free article] [PubMed]
22. Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76:1057–62. [PubMed]
23. Da Costa MM, Hogeboom CJ, Holly EA, Palefsky JM. Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant. J Infect Dis. 2002;185:1229–37. [PubMed]
24. Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the polymerase chain reaction. Science. 1991;252:1643–51. [PubMed]
25. Nuovo GJ, Becker J, Margiotta M, MacConnell P, Comite S, Hochman H. Histological distribution of polymerase chain reaction--amplified human papillomavirus 6 and 11 DNA in penile lesions. Am J Surg Pathol. 1992;16:269–75. [PubMed]
26. Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999;59:6132–6. [PubMed]
27. Tonon SA, Picconi MA, Bos PD, et al. Physical status of the E2 human papilloma virus 16 viral gene in cervical preneoplastic and neoplastic lesions. J Clin Virol. 2001;21:129–34. [PubMed]
28. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26. [PubMed]
29. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350–8. [PubMed]
30. Kinzler K, Vogelstein B. Colorectal Tumors. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis of Human Cancer. Second edition ed. McGraw-Hill Medical Publishing Division; New York: 2002. pp. 583–612.